CareLit Fachartikel

Rituximab leads to reactivation of hepatitis B in individuals with resolved infection

F Metzler, I Mederacke, MP Manns, H Wedemeyer, K Wursthorn · Zeitschrift für Gastroenterologie · 2009 · Heft 01

Dokument
1042292
CareLit-ID
Jahr
2009
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
F Metzler, I Mederacke, MP Manns, H Wedemeyer, K Wursthorn
Ausgabe
Heft 01 / 2009
Seiten
–
Erschienen: 2009-01-20 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0029-1191945

Zusammenfassung

Rituximab is an anti-CD20 antibody for the treatment of B-cell Non-Hodgkin Lymphoma (NHL) and Rheumatoid Arthritis (RA). The administration of rituximab can lead to reactivation of hepatitis B virus (HBV) infection in HBV carriers resulting in hepatic failure and death. Current guidelines recommend HBsAg testing and antiviral prophylaxis for hepatitis B carriers for a finite course. The aim of this study was to analyse the course of hepatitis B in patients with rituximab treatment. A total of 709 courses of rituximab were given to 258 hospitalized patients at the Hannover Medical School in the years 2005 to 2007…

Schlagworte

hepatitis B immunosuppression rituximab reactivation Hepatitis After Antibodies Arthritis Lead Zeitschrift für Gastroenterologie